NRF2 dependant MRP2 upregulation has been reported to be a cause of resistance towards platinum based therapy in small cell lung cancer and ovarian cancer[163,164]; Tamoxifen therapy towards breast cancer cells[165]. Here, NFE2L2 is linked to breast carcinoma.